ProfessionalsChristopher M. Wilson
Tel: +1-202-223-7301
Fax: +1-202-330-5711
cmwilson@paulweiss.com
cmwilson@paulweiss.com
Chris Wilson is a litigation partner in the Antitrust Group. Chris advises clients on a full range of antitrust matters, including merger control, cross-border antitrust investigations and private party litigation involving complex antitrust and consumer protection issues, including matters implicating the Hart-Scott-Rodino (HSR) merger review process, the Sherman Act, the Clayton Act, the FTC Act, and international and state competition statutes.
EXPERIENCE
Chris’s areas of expertise include merger enforcement, interlocking directorates, joint ventures, compliance programs, and employee “no-poach” agreements. He has advised on cross-border investigations involving the European Union, the United Kingdom, Canada, Brazil, Japan, Korea and Saudi Arabia, among other jurisdictions, and has handled merger reviews and other antitrust matters involving multiple industries, including health insurance, transportation, telecommunications, technology, energy, agriculture and biotechnology.
Prior to his private practice, Chris was a trial attorney in the Transportation, Energy & Agriculture Section of the U.S. Department of Justice’s Antitrust Division. During his time in the Division, he managed or played a key role in numerous high-profile matters, including merger reviews for Halliburton-Baker Hughes, Aetna-Humana, Anthem-Cigna, Alaska Airlines-Virgin and CVS-Aetna. Chris received the Antitrust Division’s Award of Distinction on two separate occasions.
Chris’s notable representations include:
- Endeavor Energy Resources in its $26 billion merger with Diamondback Energy;
- Envestnet in its $4.5 billion take-private deal with Bain Capital;
- Pioneer Natural Resources in its $65 billion merger with ExxonMobil;
- Platinum Equity in its $5.25 billion acquisition of Solenis;
- GE Healthcare in its $1.45 billion acquisition of BK Medical;
- Xylem in its $7.5 billion acquisition of Evoqua;
- Spark Therapeutics in its $4.3 billion sale to Roche; and
- Stone Canyon Industries in its $3 billion acquisition of Morton Salt
PROFESSIONAL AFFILIATIONS AND THOUGHT LEADERSHIP
Chris is active in the ABA’s Antitrust Section, and frequently writes and speaks on antitrust topics. A Vice Chair of the ABA Antitrust Section’s Intellectual Property Committee, and member of the Section’s Health Care and Pharmaceuticals Committee, he is a frequent participant in ABA webcasts and presentations, and an editor for the American Bar Association’s Antitrust Health Care Chronicle and Antitrust Laws & Trade Regulation: Desk Edition. Chris has also been published in numerous antitrust newsletters and publications.
While at Columbia Law School, Chris was a Harlan Fiske Stone scholar and served as an editor on the Columbia Business Law Review.